Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) (Descending) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
23155-0778-72 23155-0778 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
23155-0777-71 23155-0777 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
23155-0777-72 23155-0777 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
23155-0776-71 23155-0776 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
23155-0776-72 23155-0776 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
23155-0775-71 23155-0775 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
23155-0775-72 23155-0775 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
23155-0774-71 23155-0774 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
23155-0774-72 23155-0774 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
23155-0689-41 23155-0689 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 3, 2019 In Use
23155-0688-41 23155-0688 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 3, 2019 In Use
23155-0687-41 23155-0687 OCTREOTIDE ACETATE OCTREOTIDE ACETATE 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Sept. 3, 2019 In Use
23155-0686-31 23155-0686 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 25, 2022 In Use
23155-0685-31 23155-0685 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 25, 2022 In Use
23155-0649-41 23155-0649 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea Intravenous Oct. 1, 2019 In Use
23155-0550-31 23155-0550 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 9, 2015 In Use
23155-0549-31 23155-0549 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous June 15, 2012 In Use
23155-0548-31 23155-0548 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug. 22, 2016 In Use
23155-0548-41 23155-0548 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 9, 2015 In Use
23155-0548-42 23155-0548 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Nov. 9, 2015 In Use
23155-0547-31 23155-0547 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug. 22, 2016 In Use
23155-0547-41 23155-0547 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous June 15, 2012 In Use
23155-0547-42 23155-0547 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous June 15, 2012 In Use
23155-0529-31 23155-0529 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 22, 2012 Oct. 11, 2019 In Use
23155-0528-31 23155-0528 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 22, 2012 Oct. 11, 2019 No Longer Used
23155-0484-31 23155-0484 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 22, 2012 Oct. 11, 2019 In Use
23155-0483-31 23155-0483 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 22, 2012 Oct. 11, 2019 In Use
23155-0378-31 23155-0378 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Feb. 19, 2014 Oct. 11, 2019 In Use
23155-0378-41 23155-0378 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Feb. 19, 2014 Oct. 11, 2019 In Use
23155-0378-42 23155-0378 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Feb. 19, 2014 Oct. 11, 2019 In Use
23155-0377-31 23155-0377 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Feb. 24, 2014 Oct. 11, 2019 In Use
23155-0356-32 23155-0356 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 29, 2021 June 30, 2021 In Use
23155-0356-41 23155-0356 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 29, 2021 June 30, 2021 In Use
23155-0261-41 23155-0261 Carmustine BiCNU Chemotherapy Alkylating Agent Nitrosourea Intravenous April 4, 2013 Aug. 31, 2022 No Longer Used
23155-0240-41 23155-0240 Metoclopramide Hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Jan. 3, 2014 In Use
23155-0240-42 23155-0240 Metoclopramide Hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Jan. 3, 2014 In Use
23155-0240-43 23155-0240 Metoclopramide Hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Jan. 3, 2014 In Use
23155-0214-31 23155-0214 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 22, 2012 Aug. 11, 2020 In Use
23155-0213-31 23155-0213 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 22, 2012 Aug. 11, 2020 No Longer Used
23155-0196-31 23155-0196 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Jan. 18, 2013 In Use
23155-0196-41 23155-0196 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Jan. 18, 2013 In Use
23155-0196-42 23155-0196 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Jan. 18, 2013 In Use
23155-0196-43 23155-0196 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Jan. 18, 2013 July 31, 2020 In Use
23155-0179-31 23155-0179 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 20, 2012 In Use
23155-0179-32 23155-0179 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 20, 2012 June 21, 2012 In Use
23155-0170-31 23155-0170 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Aug. 31, 2023 In Use
23155-0168-31 23155-0168 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 13, 2012 Aug. 12, 2020 In Use
23155-0015-01 23155-0015 Estradiol Estradiol 2.0 mg/1 Hormonal Therapy Estrogen Oral Nov. 5, 2010 Sept. 23, 2019 In Use
23155-0014-01 23155-0014 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Nov. 5, 2010 Sept. 23, 2019 In Use
23155-0014-05 23155-0014 Estradiol Estradiol 1.0 mg/1 Hormonal Therapy Estrogen Oral Nov. 5, 2010 Sept. 23, 2019 In Use

Found 10,000 results in 10 milliseconds — Export these results